Correction: Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review

Nikki Bozinoff^{1

2

3}, Vitor Soares Tardelli^{4

5}, Dafna Sara Rubin-Kahana^{5

6

7}, Bernard Le Foll^{8

9

5

6

10

11

12}

Affiliations

¹ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. nikki.bozinoff@camh.ca.
² Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. nikki.bozinoff@camh.ca.
³ Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada. nikki.bozinoff@camh.ca.
⁴ Departamento de Psiquiatria, Universidade Federal de Sao Paulo, São Paulo, Brazil.
⁵ Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada.
⁶ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁷ Child, Youth, and Family Services, Centre for Addiction and Mental Health, Toronto, ON, Canada.
⁸ Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
⁹ Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.
¹⁰ Division of Neurosciences and Clinical Translation, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
¹¹ Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
¹² Waypoint Research Institute, Waypoint Centre for Mental Health Care, Penetanguishene, ON, Canada.

Published Erratum

Nikki Bozinoff et al. Harm Reduct J. 2022.

. 2022 Nov 7;19(1):123.

doi: 10.1186/s12954-022-00705-6.

Nikki Bozinoff^{1

2

3}, Vitor Soares Tardelli^{4

5}, Dafna Sara Rubin-Kahana^{5

6

7}, Bernard Le Foll^{8

9

5

6

10

11

12}

¹ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. nikki.bozinoff@camh.ca.
² Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. nikki.bozinoff@camh.ca.
³ Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada. nikki.bozinoff@camh.ca.
⁴ Departamento de Psiquiatria, Universidade Federal de Sao Paulo, São Paulo, Brazil.
⁵ Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada.
⁶ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁷ Child, Youth, and Family Services, Centre for Addiction and Mental Health, Toronto, ON, Canada.
⁸ Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
⁹ Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.
¹⁰ Division of Neurosciences and Clinical Translation, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
¹¹ Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
¹² Waypoint Research Institute, Waypoint Centre for Mental Health Care, Penetanguishene, ON, Canada.

No abstract available

Erratum for

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.
Bozinoff N, Tardelli VS, Rubin-Kahana DS, Le Foll B. Bozinoff N, et al. Harm Reduct J. 2022 Oct 13;19(1):113. doi: 10.1186/s12954-022-00695-5. Harm Reduct J. 2022. PMID: 36229831 Free PMC article.

1. Opioid and Stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada; 2021.